Skip to content
HOME Insights

Case Study: iPSC-Derived Cardiac Hypertrophy Model for Drug Screening

Explore this case study on developing a cardiac hypertrophy model using human iPSC-derived cardiomyocytes for high-throughput drug efficacy screening.
TAKE THE FIRST STEP
Case study- Development of a cardiac hypertrophy iPSC-derived disease model

Cardiovascular disease is a foremost cause of mortality worldwide, with an estimated 17.3 million deaths per year. A major obstacle for efficient drug discovery and development is the absence of physiologically relevant and predictive cell-based assays.

Human induced pluripotent stem cells (iPSCs) hold great potential as disease models for cardiovascular diseases. Not only can they recapitulate physiological features of mature cardiomyocytes, they also retain a patient's genetic background and can be produced in the large quantities required for high throughput screening platforms.

In this case study, we describe how we developed an innovative high throughput drug efficacy screening application in a model of hypertrophic cardiomyopathy, utilizing human iPSC-derived cardiomyocytes.
Topics
ABOUT US
Predict future safety and efficacy more efficiently
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.

Download the case study by
filling out the form below: